Maharashtra must be given preference in terms of vaccine supply after Hyderabad-based Bharat Biotech fulfils its commitment to the Centre of delivering Covaxin stocks that would be rolled out in the firm’s new Pune facility in three months, Maharashtra Deputy Chief Minister Ajit Pawar on May 14.
Mr Pawar reviewed the COVID-19 situation in Pune on the same day. The administration discussed mucormycosis infections being detected in some Covid-19 patients. He told that the government is working on it so that patients can get proper treatment.
“Mucormycosis patients have been identified in Pune, Pimpri-Chinchwad and rural areas. The treatment involves expensive injections, which may cost up to Rs 15 lakh. We have included the ailment under the flagship Mahatma Phule Jan Arogya Yojana (MPJAY) so that people can get treatment under the scheme,” he said.
He also mentioned that Bharat Biotech had asked for 11.58 hectares in the Pune district to set up a vaccine manufacturing plant and that the government was actively cooperating.
“Pune divisional commissioner and district collector are going to process the request for the land at the soonest. They will also work on speedy approval for the provision of water, electricity and other essentials for the plant. It may take up to three months until the vaccine production commences at the plant. The company will have to provide 50 per cent of the produced vaccine to the central government. However, we will request Bharat Biotech to reserve the rest (of the vaccine) for use within the state,” he said.
Mr Pawar also requested the Central government to transparently declare the total oxygen amount supplied to each State, details about foreign aid received and its distribution among states.
“A lot of aid is flowing in from abroad and is being routed through the Centre. So, we expect transparency on the Centre’s part to declare how much of it is being distributed to the states,” the Minister said